RU58841 and finasteride

Both are discussed in androgen-dependent hair-loss research. They act at different points in the pathway, and the quality of evidence behind them is fundamentally different.

Where androgens enter hair-follicle biology

Androgenetic alopecia is genetically influenced and androgen dependent. In susceptible scalp areas, follicles progressively miniaturise; DHT is an important signal in that process, particularly in men. That does not mean DHT is the sole cause of every kind of hair loss, or that blocking one pathway guarantees a clinical result.

The androgen receptor is the receiving point for testosterone and DHT signalling. A compound can intervene upstream by reducing DHT formation, or downstream by competing at the receptor. Finasteride and RU58841 represent those two distinct hypotheses.

Mechanism and evidence, side by side

Question	RU58841	Finasteride
Primary target	Androgen receptor antagonist; competes with androgen signalling at the receptor in preclinical models.	5-alpha-reductase inhibitor; reduces conversion of testosterone to DHT.
What it does not do	It is not shown to lower DHT production.	It has no affinity for the androgen receptor according to its regulator-reviewed label.
Hair evidence	Cell, tissue-graft, and animal models; no publicly assessable clinical result establishing efficacy.	Randomised, placebo-controlled human trials and regulator-reviewed clinical data for male pattern hair loss.
What can be concluded	A plausible experimental mechanism—not proven clinical benefit, safety, or superiority.	An established medicine with known benefits, limitations, contraindications, and adverse-effect warnings.

What the RU58841 studies actually show

Early receptor and animal experiments found that RU58841 could competitively suppress DHT-driven androgen receptor activity. A stumptailed-macaque model reported increases in hair density, thickness, and length after topical exposure. A separate experiment found that RU58841 antagonised testosterone-related growth inhibition in a macaque dermal-papilla-cell model.

These results explain why the compound became interesting to hair researchers. They do not demonstrate that a finished formulation is effective or safe in people. Species, vehicle, exposure, outcome measurement, and study design all limit transfer from a model to clinical use.

Why finasteride is not an equivalent benchmark

Finasteride inhibits type II 5-alpha-reductase and thereby lowers scalp and serum DHT. Its clinical programme included randomised placebo-controlled trials in men with androgenetic alopecia, with hair-count and photographic endpoints. That body of evidence supports an approved indication; it also defines warnings and limitations that should be discussed with a qualified clinician.

There is no direct clinical RU58841-versus-finasteride trial that justifies calling RU58841 more effective, safer, or more local. Different mechanism does not mean equal evidence, and absence of published outcome data is not evidence of absence of risk.

Primary and regulator sources

The links below lead to original studies, trial registrations, or regulator-reviewed information.